Cite
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults.
MLA
Juergens, Christine, et al. “Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine Formulations with and without Aluminum Phosphate and Comparison of the Formulation of Choice with 23-Valent Pneumococcal Polysaccharide Vaccine in Elderly Adults.” Human Vaccines & Immunotherapeutics, vol. 10, no. 5, May 2014, pp. 1–11. EBSCOhost, https://doi.org/10.4161/hv.27998.
APA
Juergens, C., de Villiers, P. J. T., Moodley, K., Jayawardene, D., Jansen, K. U., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2014). Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults. Human Vaccines & Immunotherapeutics, 10(5), 1–11. https://doi.org/10.4161/hv.27998
Chicago
Juergens, Christine, Pierre J. T. de Villiers, Keymanthri Moodley, Deepthi Jayawardene, Kathrin U. Jansen, Daniel A. Scott, Emilio A. Emini, William C. Gruber, and Beate Schmoele-Thoma. 2014. “Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine Formulations with and without Aluminum Phosphate and Comparison of the Formulation of Choice with 23-Valent Pneumococcal Polysaccharide Vaccine in Elderly Adults.” Human Vaccines & Immunotherapeutics 10 (5): 1–11. doi:10.4161/hv.27998.